Welcome to our dedicated page for Oaktree Acquisition III SEC filings (Ticker: OACC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SEC filings for Oaktree Acquisition Corp. III Life Sciences (OACC), a Cayman Islands blank check shell company in the Financial Services sector. Its filings with the U.S. Securities and Exchange Commission include an Annual Report on Form 10-K and current reports on Form 8-K describing material corporate events.
Through these filings, readers can review details about the company’s capital structure, including its units (OACCU), Class A ordinary shares (OACC), and redeemable warrants (OACCW) listed on The Nasdaq Stock Market LLC. The filings explain that each unit consists of one Class A ordinary share and one-fifth of one redeemable warrant, and that each whole warrant is exercisable for one Class A ordinary share at a specified exercise price.
Form 8-K reports for OACC cover topics such as the appointment and resignation of key officers, including the Chief Financial Officer, and the election of independent directors to the board. These reports often describe committee assignments on the audit, nominating, and compensation committees, independence determinations under Nasdaq and Exchange Act rules, and the absence of direct compensation or employment agreements for certain appointees. They also reference indemnity and letter agreements and potential opportunities for non-controlling minority investments in Oaktree Acquisition Holdings III LS, LLC, as discussed in the company’s Form 10-K.
On this filings page, users can review OACC’s 10-K and 8-K documents and use AI-powered summaries to understand the key points in each report. The platform highlights important information about governance, board composition, officer roles, and the structure of the company’s Nasdaq-listed securities, helping readers interpret lengthy regulatory documents more efficiently.
Oaktree Acquisition Corp. III Life Sciences filed its Q3 2025 10‑Q, showing interest-driven profits while it continues to search for a merger target. Net income was $1,966,742 for the quarter, primarily from $2,192,321 of interest on funds held in trust. For the nine months, net income totaled $5,499,876. Cash held in the Trust Account was $199,769,089 as of September 30, 2025, tied to 19,199,029 Class A shares subject to redemption at $10.41 per share.
Operating cash use was modest, with cash on hand of $1,328,841 and working capital of $254,086. The company remains a SPAC with no revenues before a business combination and faces a deadline of October 25, 2026 to complete a deal. Management disclosed that these conditions raise substantial doubt about its ability to continue as a going concern. As of November 13, 2025, there were 19,783,010 Class A and 4,799,758 Class B shares outstanding, and 3,956,601 warrants in total. The IPO’s over‑allotment was partially exercised, and 231,492 Class B shares were forfeited accordingly.
Oaktree Acquisition Corp. III Life Sciences (OACC) reported an insider ownership update. The company’s Chief Financial Officer, George Martinez, filed a Form 3 initial statement under Section 16, effective 10/29/2025. The filing states that no securities are beneficially owned. The submission includes Exhibit 24 (Power of Attorney) and is filed by one reporting person.
Oaktree Acquisition Corp. III Life Sciences (OACC) reported a leadership change. On October 29, 2025, Chief Financial Officer Thomas Sweeney resigned, and the Board appointed George A. Martinez as CFO (principal accounting and principal financial officer), effective immediately. The company stated Mr. Sweeney’s resignation was not due to disagreements with the Board or management.
Mr. Martinez is a Senior Vice President in Oaktree’s finance organization and a Certified Public Accountant. He previously served as an Audit Senior Manager at Ernst & Young from 2013 to 2024. He will not be compensated by the Company for his CFO role and has no employment agreement. He is expected to enter into standard indemnity and letter agreements on the same terms as other directors and officers. No related‑party transactions or family relationships were disclosed.
Oaktree Acquisition Corp. III Life Sciences (OACC) filed a Form 3 disclosing director David Berry’s initial beneficial ownership status. The filing states that he beneficially owns no securities of OACC. The event date is 10/17/2025, and the form was filed by one reporting person. The submission includes an Exhibit 24 Power of Attorney.
Oaktree Acquisition Corp. III Life Sciences (OACC) appointed David A. Berry, MD, PhD as an independent director effective October 17, 2025. He will serve as a Class II director and join the audit, nominating, and compensation committees. The Board determined he meets independence standards under Nasdaq and Rule 10A-3.
Dr. Berry will not receive director compensation. Consistent with disclosures in the company’s 10-K, he is expected to have an opportunity to make a non‑controlling minority investment in Oaktree Acquisition Holdings III LS, LLC, and to enter standard Letter and Indemnity Agreements used for other directors and officers. No related-party transactions or family relationships were disclosed.
FAQ
What is the current stock price of Oaktree Acquisition III (OACC)?
What is the market cap of Oaktree Acquisition III (OACC)?
